Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium

Antibody–drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the research and development of anti-tumor antibody drugs. Every year, exciting new development...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jiazheng, Wu, Siyu, Li, Rong, Jiang, Yuanhong, Zheng, Jianyi, Li, Zeyu, Li, Mingyang, Xin, Kerong, Guan, Xiaojiao, Li, Shijie, Chen, Xiaonan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385919/
https://www.ncbi.nlm.nih.gov/pubmed/37507780
http://dx.doi.org/10.1186/s13045-023-01475-9
_version_ 1785081531835875328
author Yu, Jiazheng
Wu, Siyu
Li, Rong
Jiang, Yuanhong
Zheng, Jianyi
Li, Zeyu
Li, Mingyang
Xin, Kerong
Guan, Xiaojiao
Li, Shijie
Chen, Xiaonan
author_facet Yu, Jiazheng
Wu, Siyu
Li, Rong
Jiang, Yuanhong
Zheng, Jianyi
Li, Zeyu
Li, Mingyang
Xin, Kerong
Guan, Xiaojiao
Li, Shijie
Chen, Xiaonan
author_sort Yu, Jiazheng
collection PubMed
description Antibody–drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the research and development of anti-tumor antibody drugs. Every year, exciting new developments and innovations in the treatment of urological tumors are introduced at the American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. In this article, we summarize some of the most impressive advances in new clinical trials and clinical data on ADCs in the 2023 ASCO-GU Cancers Symposium for the treatment of urothelial carcinoma.
format Online
Article
Text
id pubmed-10385919
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103859192023-07-30 Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium Yu, Jiazheng Wu, Siyu Li, Rong Jiang, Yuanhong Zheng, Jianyi Li, Zeyu Li, Mingyang Xin, Kerong Guan, Xiaojiao Li, Shijie Chen, Xiaonan J Hematol Oncol Correspondence Antibody–drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the research and development of anti-tumor antibody drugs. Every year, exciting new developments and innovations in the treatment of urological tumors are introduced at the American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. In this article, we summarize some of the most impressive advances in new clinical trials and clinical data on ADCs in the 2023 ASCO-GU Cancers Symposium for the treatment of urothelial carcinoma. BioMed Central 2023-07-28 /pmc/articles/PMC10385919/ /pubmed/37507780 http://dx.doi.org/10.1186/s13045-023-01475-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Yu, Jiazheng
Wu, Siyu
Li, Rong
Jiang, Yuanhong
Zheng, Jianyi
Li, Zeyu
Li, Mingyang
Xin, Kerong
Guan, Xiaojiao
Li, Shijie
Chen, Xiaonan
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
title Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
title_full Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
title_fullStr Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
title_full_unstemmed Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
title_short Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
title_sort novel adcs and combination therapy in urothelial carcinoma: latest updates from the 2023 asco-gu cancers symposium
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385919/
https://www.ncbi.nlm.nih.gov/pubmed/37507780
http://dx.doi.org/10.1186/s13045-023-01475-9
work_keys_str_mv AT yujiazheng noveladcsandcombinationtherapyinurothelialcarcinomalatestupdatesfromthe2023ascogucancerssymposium
AT wusiyu noveladcsandcombinationtherapyinurothelialcarcinomalatestupdatesfromthe2023ascogucancerssymposium
AT lirong noveladcsandcombinationtherapyinurothelialcarcinomalatestupdatesfromthe2023ascogucancerssymposium
AT jiangyuanhong noveladcsandcombinationtherapyinurothelialcarcinomalatestupdatesfromthe2023ascogucancerssymposium
AT zhengjianyi noveladcsandcombinationtherapyinurothelialcarcinomalatestupdatesfromthe2023ascogucancerssymposium
AT lizeyu noveladcsandcombinationtherapyinurothelialcarcinomalatestupdatesfromthe2023ascogucancerssymposium
AT limingyang noveladcsandcombinationtherapyinurothelialcarcinomalatestupdatesfromthe2023ascogucancerssymposium
AT xinkerong noveladcsandcombinationtherapyinurothelialcarcinomalatestupdatesfromthe2023ascogucancerssymposium
AT guanxiaojiao noveladcsandcombinationtherapyinurothelialcarcinomalatestupdatesfromthe2023ascogucancerssymposium
AT lishijie noveladcsandcombinationtherapyinurothelialcarcinomalatestupdatesfromthe2023ascogucancerssymposium
AT chenxiaonan noveladcsandcombinationtherapyinurothelialcarcinomalatestupdatesfromthe2023ascogucancerssymposium

Ejemplares similares